Physician profile
Jonathan Ramsey
NPI 1225456858
$8,164.05
in general payments reported to CMS, 2019-2025
23 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $14.24 · 2021: $589 · 2022: $1,139 · 2023: $2,548 · 2024: $1,616 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,267 · Long Term Medical Supply Or Device Loan: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,267.32 |
| Long Term Medical Supply Or Device Loan | $1,331.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,774.17 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Carl Zeiss Meditec USA, INC. | $1,331.45 | 2023 | Artevo 800 |
| Abbvie INC. | $516.45 | 2023-2025 | |
| Allergan, INC. | $306.05 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $296.81 | 2021 | |
| Sight Sciences, INC. | $264.13 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $227.05 | 2022-2024 | Tecnis Simplicity, Tecnis Iol |
| Alexion Pharmaceuticals, INC. | $168.47 | 2024 | Soliris, Ultomiris |
| Sun Pharmaceutical Industries INC. | $157.10 | 2022-2025 | Cequa |
| Ivantis, INC | $150.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $144.80 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $133.56 | 2023 | |
| Glaukos Corporation | $133.56 | 2021-2025 | Idosetr, Idose |
| Oyster Point Pharma, INC. | $124.41 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $110.70 | 2022-2025 | Xiidra, Miebo, Lotemax Sm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $78.80 | 2022-2023 | |
| Rxsight INC | $68.56 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| New World Medical,INC. | $68.43 | 2022-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Ocular Therapeutix, INC. | $32.81 | 2022-2024 | Dextenza |
| Thea Pharma INC. | $24.92 | 2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $24.26 | 2025 | Acthar |
| Eyepoint US, INC. | $15.87 | 2021 | |
| Shire North American Group INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.